Merck & Company (MRK) Gets a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Merck & Company, with a price target of $109.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Moderna. According to TipRanks, Flynn has an average return of 9.8% and a 56.21% success rate on recommended stocks.
In addition to Morgan Stanley, Merck & Company also received a Hold from Bernstein’s Courtney Breen in a report issued on April 3. However, on April 8, Guggenheim maintained a Buy rating on Merck & Company (NYSE: MRK).
Based on Merck & Company’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $16.4 billion and a net profit of $2.96 billion. In comparison, last year the company earned a revenue of $15.62 billion and had a net profit of $3.74 billion
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year. Most recently, in February 2026, Chirfi Guindo, the CMO of MRK sold 10,000.00 shares for a total of $1,214,500.00.
Read More on MRK:
Disclaimer & DisclosureReport an Issue
- Merck begins tender offer to acquire Terns Pharmaceuticals
- Evaxion Biotech reports last patient visit in one-year extension of EVX-01 trial
- Compugen initiated with a Buy at Lake Street
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports
- Merck price target raised to $135 from $125 at JPMorgan
